ethyl 3-amino-3-pyridin-2-ylpropanoate | 77742-21-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 3-amino-3-pyridin-2-ylpropanoate
• 英文别名: Ethyl 3-amino-3-(pyridin-2-yl)propanoate
• CAS: 77742-21-3
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: USADZNHVKXZURN-UHFFFAOYSA-N

物化性质

• 沸点：
  310.6±32.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-3-pyridin-2-ylpropanoate 在 N-溴代丁二酰亚胺(NBS) 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 9.0h， 生成 ethyl (3-bromoimidazo[1,5-a]pyridin-1-yl)acetate
  参考文献：
  名称：

  New CRTh2 antagonists

  摘要：

  本发明涉及式(I)的化合物，制备这种化合物的方法以及它们在治疗病理状况或疾病中的应用，该病理状况或疾病容易通过CRTh2拮抗活性得到改善。

  公开号：

  EP2548876A1
• 作为产物：
  描述：

  ethyl 3-(1,1-dimethylethylsulfinamido)-3-(pyridin-2-yl)propanoate 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以99.9%的产率得到ethyl 3-amino-3-pyridin-2-ylpropanoate
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES

  摘要：

  本文提供了包含所述化合物的药物组合物，用于治疗癌症。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。

  公开号：

  WO2020214734A1

文献信息

• [EN] NEW CRTH2 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE CRTH2
  申请人：ALMIRALL SA

  公开号：WO2013010880A1

  公开（公告）日：2013-01-24

  The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过CRTh2拮抗活性得到改善。
• Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
  申请人：——

  公开号：US20030073723A1

  公开（公告）日：2003-04-17

  The present invention relates to novel imidazolidine derivatives of formula I, 1 wherein A, E, Z, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutical active compounds which are suitable, for example, for the treatment of inflammatory diseases, including rheumatoid arthritis, or allergic diseases. The compounds of formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the treatment of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on the interactions of VLA-4 receptors with their ligands play a role. The invention furthermore relates to processes for the preparation of the compounds of formula I, their use and pharmaceutical preparations which contain compounds of formula I.

  本发明涉及具有以下式I的新型咪唑啉衍生物， 其中A、E、Z、R1、R2、R3、R4和R5在权利要求中所示。式I的化合物是有价值的药用活性化合物，例如适用于治疗炎症性疾病，包括类风湿关节炎或过敏性疾病。式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于粘附受体VLA-4的拮抗剂。它们通常适用于由白细胞粘附和/或白细胞迁移的不良程度引起的疾病的治疗，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用起作用的疾病。此外，本发明还涉及制备式I化合物的方法，它们的用途以及含有式I化合物的药物制剂。
• [EN] USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZO[B]THIAZINE EN TANT QU'AGENTS CYTOPROTECTEURS
  申请人：MEDEIA THERAPEUTICS LTD

  公开号：WO2014191632A1

  公开（公告）日：2014-12-04

  The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

  本发明涉及芳基噻嗪化合物、代谢物、N-氧化物、酰胺、酯、药用可接受盐、水合物和溶剂合物，以及它们在治疗或预防涉及中枢神经系统或身体周围存在异常细胞脂质过氧化的疾病或状态中作为细胞保护剂的用途。本发明还涉及它们的制备方法以及包含作为活性成分的上述化合物之一或多个的药物组合物。
• Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists
  作者：Maria Antonia Buil、Marta Calbet、Marcos Castillo、Jordi Castro、Cristina Esteve、Manel Ferrer、Pilar Forns、Jacob González、Sara López、Richard S. Roberts、Sara Sevilla、Bernat Vidal、Laura Vidal、Pere Vilaseca

  DOI：10.1016/j.ejmech.2016.02.023

  日期：2016.5

  Monocyclic and bicyclic ring systems were investigated as the “core” section of a series of diphenylsulphone-containing acetic acid CRTh2 receptor antagonists. A range of potencies were observed and single-digit nanomolar potencies were obtained in both the monocyclic and bicyclic cores. Residence times for the monocyclic compounds were very short. Some of the bicyclic cores displayed better residence

  研究了单环和双环系统，将其作为一系列含二苯砜的乙酸CRTh2受体拮抗剂的“核心”部分。在单环和双环核中均观察到一定范围的效力，并获得了单位数纳摩尔的效力。单环化合物的停留时间非常短。一些双环核显示出更好的停留时间。在核心的北部，头部和尾部之间的甲基是开始长停留时间的必要条件。尾部取代的变化最大限度地提高了效力和停留时间。
• [EN] BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2020214734A1

  公开（公告）日：2020-10-22

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  本文提供了包含所述化合物的药物组合物，用于治疗癌症。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。